Evidence map›Paper›PMID 32127273›Full record

ReviewJournal of cardiothoracic and vascular anesthesia2020

The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite.

Dheeraj Goswami, Matthew DiGiusto, Rajeev Wadia, Sean Barnes, Jamie Schwartz, Diana Steppan, Kristen Nelson-McMillan, Richard Ringel, Jochen Steppan

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cardiothoracic and vascular anesthesia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Dheeraj GoswamiDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD.
Matthew DiGiustoDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD; Department of Pediatrics, Johns Hopkins University, School of Medicine, Baltimore, MD.
Rajeev WadiaDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD.
Sean BarnesDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD.
Jamie SchwartzDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD.
Diana SteppanDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD.
Kristen Nelson-McMillanDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD; Department of Pediatrics, Johns Hopkins University, School of Medicine, Baltimore, MD.
Richard RingelDepartment of Pediatrics, Johns Hopkins University, School of Medicine, Baltimore, MD.
Jochen SteppanDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD. Electronic address: J.Steppan@jhmi.edu.
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

The Therapeutic Role for LOLX2 in Pulmonary HypertensionK08HL145132 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI STEPPAN, JOCHEN · 2019 to 2023
$859k
NHLBI NIH HHS K08 HL145132
6 · The paper itself

Abstract

Anticoagulation is an essential component for patients undergoing cardiopulmonary bypass or extracorporeal membrane oxygenation and for those with ventricular assist devices. However, thrombosis and bleeding are common complications. Heparin continues to be the agent of choice for most patients, likely owing to practitioners' comfort and experience and the ease with which the drug's effects can be reversed. However, especially in pediatric cardiac surgery, there is increasing interest in using bivalirudin as the primary anticoagulant. This drug circumvents certain problems with heparin administration, such as heparin resistance and heparin-induced thrombocytopenia, but it comes with additional challenges. In this manuscript, the authors review the literature on the emerging role of bivalirudin in pediatric cardiac surgery, including its use with cardiopulmonary bypass surgery, extracorporeal membrane oxygenation, ventricular assist devices, and interventional cardiology. Moreover, they provide an overview of bivalirudin's pharmacodynamics and monitoring methods.

Indexed as

Cardiac Surgical ProceduresCardiologyAnticoagulantsCardiopulmonary BypassChildHeparinHirudinsHumansPeptide FragmentsRecombinant ProteinsAnticoagulantsbivalirudinHeparinHirudinsPeptide FragmentsRecombinant Proteinsanticoagulationbivalirudincardiopulmonary bypassECMOpediatric cardiac surgery

Identifiers

PMID32127273
PMCPMC7321892
OpenAlexW3001842711

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.